Retatrutide is still an investigational drug — nobody can walk into a pharmacy and buy it anywhere on earth. But this week the picture shifted slightly. On Monday 3 August 2026, Eli Lilly confirmed it has built a formal expanded access ("compassionate use") programme for retatrutide, meaning a small number of patients can now apply to receive the triple-agonist before retatrutide FDA approval. It is not a launch, it is not a rollout, and the eligibility bar is deliberately high — but it is the first time Lilly has publicly described a pre-approval supply channel with rules attached.

Here's what actually changed, what the criteria are, and what it does (and doesn't) tell us about timing.

What Lilly actually announced

Six weeks ago, STAT News reported that Lilly and the US FDA had allowed a single 79-year-old patient with refractory obesity, obstructive sleep apnoea and pulmonary hypertension to receive retatrutide through the FDA's expanded access pathway — a request made by an NIH clinician. The story drew attention partly because compassionate use is normally reserved for cancer and rare disease, and partly because the patient's identity was never disclosed.

After other doctors asked for the same thing for their own patients and got no reply, Lilly responded. A company spokesperson told STAT and Reuters that for a limited number of patients who meet specific medical criteria and cannot enrol in a clinical trial, it considers it "medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA's guidance," and that it is now actively reviewing requests from health care providers.

That's the news: a formalised, physician-initiated application process, replacing what looked like a one-off arrangement.

The four criteria — and why most people won't qualify

Per Reuters' reporting of Lilly's statement, an applicant must be:

  • 18 or older
  • Refractory to existing therapy — still severely affected despite tolerating the highest approved dose of an approved obesity medication (in practice, that means having already been through something like tirzepatide or semaglutide at maximum dose)
  • Living with at least two serious or life-threatening obesity-related complications for which they are actively receiving care
  • Unable to enrol in an active clinical trial

Every case also runs through three separate reviews: Lilly, the FDA, and an institutional review board. A patient cannot apply directly; the treating doctor has to do it.

Stack those together and the eligible population is tiny. This is a pathway for the sickest end of the spectrum — someone with, say, treatment-resistant severe obesity plus heart failure and pulmonary hypertension — not for people who simply want the strongest drug in the class earlier. It's worth being blunt about that, because the gap between "a programme exists" and "I can get it" is enormous here.

The part most coverage misses: the company is the gatekeeper

The FDA authorises the overwhelming majority of expanded access requests it receives — the regulator has rarely been the bottleneck. Under the 21st Century Cures Act, manufacturers must publish their expanded access policies, but nothing compels a company to say yes to any individual request. Whether a given patient gets an investigational drug early is, legally, the sponsor's call.

That's the structural lesson from this week, and it travels across borders. Pre-approval access schemes exist in most developed markets, but they all depend on a manufacturer being willing to ship product.

The Australian read-through

Australia has its own version: the TGA's Special Access Scheme, where a doctor applies for an unapproved medicine for a single named patient (Category B involves a written clinical justification and a TGA approval letter). Every so often we get asked whether an Australian could use the SAS to get retatrutide now. The mechanism is real — but the same constraint applies as in the US. SAS approval is permission to import and supply; it is not a supply. If Lilly's expanded access programme is currently a narrow, US-centred, three-layer-review process, an Australian SAS application has nowhere to source authentic product from. Our Australia page and how the pathways work cover this in more detail: for Australians, the realistic route remains TGA registration after Lilly's regulatory filings, which the company has signalled from 2027.

Does this tell us anything about retatrutide FDA approval timing?

Honestly: very little, and it's worth resisting the temptation to read it as a signal. Expanded access programmes sit in the space between trial and approval. They indicate a sponsor has enough manufacturing headroom and safety confidence to hand out product outside a protocol — which is not nothing — but historically they carry no read-through to approval dates or to how broad a label will be. The gating events are still the pivotal data and the regulatory submission.

On the data, the case is unusually strong for a drug still pre-filing. TRIUMPH-1 reported average weight loss of about 28.3% at the 12mg dose over 80 weeks, with 45.3% of participants losing 30% or more of their body weight. TRIUMPH-4, in people with obesity and knee osteoarthritis, reported both substantial weight loss and large reductions in WOMAC pain scores, with Lilly stating more than one in eight treated patients were completely free of knee pain at trial end. Lilly has said further Phase 3 readouts are expected through 2026, and TRANSCEND-T2D-1 results in type 2 diabetes have been published in The Lancet.

Two caveats worth repeating. Several of these results have been communicated first via company press releases and conference presentations, with peer-reviewed publication following later — press release data is not the same as a published paper with full tables. And the expanded access programme itself has been described in statements to journalists rather than in a detailed public protocol, so the finer points may evolve.

What this means if you're just waiting

For the vast majority of people watching retatrutide anywhere in the world, nothing about this week changes your timeline. The practical takeaway is narrower and more useful: if you or someone you care for is genuinely at the severe, complication-heavy end of obesity and has already exhausted maximum-dose approved therapy, this is now a conversation worth having with a specialist rather than a closed door. For everyone else, the sequence is unchanged — remaining Phase 3 readouts, then filings, then approvals country by country. Our safety page tracks what the tolerability data looks like as it accumulates.

If you want the next readout, filing or approval decision as it lands, join the free updates list — plain-language, no spam.

FAQ

Can you get retatrutide before FDA approval?

In very limited circumstances, yes. Lilly confirmed on 3 August 2026 that it has a formal expanded access programme, but applicants must be 18+, have refractory obesity despite the highest approved dose of an existing obesity medicine, have at least two serious or life-threatening obesity-related complications under active care, and be unable to join a clinical trial — and a doctor must apply on their behalf.

When will retatrutide be available?

There is still no approval anywhere in the world. Lilly has said additional Phase 3 readouts are expected through 2026, with regulatory filings signalled from 2027, so approvals in major markets would realistically follow after that. The expanded access programme does not accelerate that timeline.

What is expanded access or compassionate use?

It's a pathway allowing patients with serious or life-threatening conditions to receive an investigational medicine outside a clinical trial when no comparable option exists. The regulator authorises the great majority of requests it sees, but the manufacturer decides whether to supply — so in practice the company is the gatekeeper.

Is retatrutide approved in Australia?

No. Retatrutide is not TGA-approved and cannot be prescribed as a registered medicine in Australia. Australia's Special Access Scheme allows a doctor to apply for an unapproved medicine for a named patient, but that permission still relies on being able to source authentic product from the manufacturer.

Sources

Disclaimer: This article is general information only and is not medical advice. Retatrutide is investigational and is not approved by the TGA, the FDA or any other regulator. Nothing here should be used to make treatment decisions — speak to your GP or a specialist about your own situation. retatrutide.net.au is an independent Australian information site and is not affiliated with, endorsed by or sponsored by Eli Lilly and Company.